Status:
TERMINATED
Oral Green Tea Extract and Milk Thistle Extract to Colorectal Cancer Patients Undergoing Resection
Lead Sponsor:
Richard Whelan
Collaborating Sponsors:
St. Luke's-Roosevelt Hospital Center
Conditions:
Colon Cancer
Eligibility:
All Genders
18-85 years
Phase:
PHASE1
Brief Summary
Colorectal cancer is the third most common form of cancer found in the United States. To date surgical resection provides the best chance for cure. Unfortunately, despite "curative" surgery, tumor rec...
Detailed Description
Green tea extract and Silibinin (from the milk thistle plant) have both been shown in experimental studies to have anti-cancer effects as well as limited toxicity. Epigallocatechin-3-gallate (EGCG) is...
Eligibility Criteria
Inclusion
- Patients must be age 18 to 85 years
- Patient must have biopsy proven colon or rectal cancer
- Cancer should be judged to be stage 1 to 3 based on preoperative staging
- Patients may be any race and any gender
Exclusion
- Patients with cancer judged to be stage 4 are not eligible
- Patients undergoing emergency surgery for cancer are not eligible
- Patients who are immunosuppressed or taking immunosuppressive medications (steroids or chemotherapeutic agents) are not eligible
- Patients with Crohn's disease or ulcerative colitis are not eligible
- Patients with other malignancies are not eligible
- Patients who are taking part in other neoadjuvant and early adjuvant chemotherapy trials are not eligible
Key Trial Info
Start Date :
July 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2023
Estimated Enrollment :
23 Patients enrolled
Trial Details
Trial ID
NCT01239095
Start Date
July 1 2011
End Date
February 1 2023
Last Update
February 22 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mount Sinai St. Luke's Roosevelt Hospital Center
New York, New York, United States, 10019